Bio firm announces commercial-scale manufacturing milestone for PH-762
Phio Pharmaceuticals released its first cGMP batch of PH-762, the active ingredient for its skin cancer treatment, supporting supply chain readiness for a Phase 2b trial planned for 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed